Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR1 | Q92633 | 17/20 | 0.67 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.67 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.67 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.67 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.67 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.67 |
| ▸ | ABCB4 | P21439 | 1/20 | 0.67 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.67 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.67 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.67 |
| ▸ | LPAR3 | Q9UBY5 | 5/20 | 0.46 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.45 |
| ▸ | MGLL | Q99685 | 1/20 | 0.43 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HRH1 | P35367 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2636704 | 0.97 | LPAR1 (0.64) | LPAR1ABCC3ABCC4ABCB11CYP2C8 | |
| SCHEMBL2635823 | 0.96 | LPAR1 (0.63) | LPAR1ABCC3ABCC4ABCB11CYP2C8 | |
| SCHEMBL2761361 | 0.95 | LPAR1 (0.61) | LPAR1ABCC3ABCC4ABCB11CYP2C8 | |
| SCHEMBL2635443 | 0.94 | LPAR1 (0.61) | LPAR1ABCC3ABCC4ABCB11CYP2C8 | |
| SCHEMBL2636093 | 0.92 | LPAR1 (0.60) | LPAR1ABCC3ABCC4ABCB11CYP2C8 | |
| SCHEMBL2636366 | 0.92 | LPAR1 (0.60) | LPAR1ABCC3ABCC4ABCB11CYP2C8 | |
| SCHEMBL7596 | 0.92 | LPAR1 (0.57) | LPAR1ABCC3ABCC4ABCB11CYP2C8 | |
| SCHEMBL2635732 | 0.91 | LPAR1 (0.59) | LPAR1ABCC3ABCC4ABCB11CYP2C8 | |
| SCHEMBL2761323 | 0.91 | LPAR1 (0.56) | LPAR1ABCC3ABCC4ABCB11CYP2C8 | |
| SCHEMBL2761388 | 0.91 | LPAR1 (0.61) | LPAR1ABCC3ABCC4ABCB11CYP2C8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2648726-A1 | POLYCYCLIC LPA1 ANTAGONIST AND USES THEREOF | Amira Pharmaceuticals, Inc. (US) | 2013-10-16 | — | — | EP | claimed |
| WO-2012078805-A1 | POLYCYCLIC LPA1 ANTAGONIST AND USES THEREOF | AMIRA PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | WO | claimed |
| EP-2438048-A2 | POLYCYCLIC ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS | Amira Pharmaceuticals, Inc. (US) | 2012-04-11 | — | — | EP | claimed |
| WO-2011159632-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS FOR THE TREATMENT OF CONDITIONS OR DISEASES OF THE EYE | AMIRA PHARMACEUTICALS, INC. (US) | 2011-12-22 | — | — | WO | claimed |
| WO-2011159633-A1 | INHALABLE FORMULATIONS OF LYSOPHOSPHATDIC ACID RECEPTOR ANTAGONISTS | AMIRA PHARMACEUTICALS, INC. (US) | 2011-12-22 | — | — | WO | claimed |
| WO-2011159635-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONIST FOR THE TREATMENT OF DERMAL CONDITIONS | AMIRA PHARMACEUTICALS, INC. (US) | 2011-12-22 | — | — | WO | claimed |
| WO-2010141761-A2 | POLYCYCLIC ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-12-09 | — | — | WO | claimed |
| WO-2010141768-A2 | POLYCYCLIC ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-12-09 | — | — | WO | claimed |
| US-9987381-B2 | Radioligands for imaging the LPA-1 receptor | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-06-05 | — | — | US | disclosed |
| US-20160256577-A1 | RADIOLIGANDS FOR IMAGING THE LPA-1 RECEPTOR | BRISTOL MYERS SQUIBB CO (US) | 2016-09-08 | — | — | US | disclosed |
| EP-3062827-A1 | RADIOLIGANDS FOR IMAGING THE LPA-1 RECEPTOR | Bristol-Myers Squibb Company (US) | 2016-09-07 | — | — | EP | disclosed |
| WO-2015066456-A1 | RADIOLIGANDS FOR IMAGING THE LPA-1 RECEPTOR | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-05-07 | — | — | WO | disclosed |
| CN-103596566-A | Polycyclic LPA1 antagonists and uses thereof | AMIRA PHARMACEUTICALS INC | 2014-02-19 | — | — | CN | disclosed |
| EP-2648726-A1 | POLYCYCLIC LPA1 ANTAGONIST AND USES THEREOF | Amira Pharmaceuticals, Inc. (US) | 2013-10-16 | — | — | EP | disclosed |
| WO-2011159635-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONIST FOR THE TREATMENT OF DERMAL CONDITIONS | AMIRA PHARMACEUTICALS, INC. (US) | 2011-12-22 | — | — | WO | disclosed |
| WO-2011159632-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS FOR THE TREATMENT OF CONDITIONS OR DISEASES OF THE EYE | AMIRA PHARMACEUTICALS, INC. (US) | 2011-12-22 | — | — | WO | disclosed |
| WO-2011159633-A1 | INHALABLE FORMULATIONS OF LYSOPHOSPHATDIC ACID RECEPTOR ANTAGONISTS | AMIRA PHARMACEUTICALS, INC. (US) | 2011-12-22 | — | — | WO | disclosed |
| WO-2011041694-A2 | COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | AMIRA PHARMACEUTICALS, INC. (US) | 2011-04-07 | — | — | WO | disclosed |
| WO-2010141768-A2 | POLYCYCLIC ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-12-09 | — | — | WO | disclosed |
| WO-2010141761-A2 | POLYCYCLIC ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160256577-A1 | RADIOLIGANDS FOR IMAGING THE LPA-1 RECEPTOR | LPAR1, LPAR3, LPAR2 | LPAR1 1/4885ABCC3 2753/4885ABCC4 3076/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.